[go: up one dir, main page]

WO2021243201A1 - Compositions topiques pour le traitement de la douleur neuropathique périphérique - Google Patents

Compositions topiques pour le traitement de la douleur neuropathique périphérique Download PDF

Info

Publication number
WO2021243201A1
WO2021243201A1 PCT/US2021/034845 US2021034845W WO2021243201A1 WO 2021243201 A1 WO2021243201 A1 WO 2021243201A1 US 2021034845 W US2021034845 W US 2021034845W WO 2021243201 A1 WO2021243201 A1 WO 2021243201A1
Authority
WO
WIPO (PCT)
Prior art keywords
anandamide
topical
neuropathic pain
fatty acid
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2021/034845
Other languages
English (en)
Inventor
S. Narasimha MURTHY
Anitha POLICE
Vijaykumar SHANKAR
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Mississippi
Original Assignee
University of Mississippi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Mississippi filed Critical University of Mississippi
Publication of WO2021243201A1 publication Critical patent/WO2021243201A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone

Definitions

  • Topical compositions including anandamide are known to be unstable, and anandamide is difficult to retain in skin because it is a small molecule. [0011] Accordingly, it would be desirable to provide an effective and safe topical product available for the management of peripheral neuropathic pain.
  • Fig. 2A demonstrates taxifolin (TX) as the constituent
  • Fig. 2B demonstrates silychristin (SC) as the constituent
  • Fig. 2C demonstrates silydinain (SD) as the constituent
  • Fig. 2D demonstrates silybin (SB) as the constituent
  • Fig. 2E demonstrates isosilybin (IS) as the constituent.
  • Fig. 3 is a graphical depiction of an example embodiment of a phase solubility curve of anandamide and silybin.
  • the novel topical formulations further include at least one cannabinoid selected from delta 8-tetrahydrocannabinol, delta 9-tetrahydrocannabinol, cannabidiol, cannabinol, cannabigerol, cannabichromene, dronabinol, nabilone, and combinations thereof.
  • the cannabinoids may produce a synergistic effect to treat peripheral neuropathic pain.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne de nouvelles compositions topiques pour le traitement de la douleur neuropathique périphérique. Les compositions topiques comprennent un cannabinoïde et un inhibiteur d'hydrolase d'amide d'acide gras ou un inhibiteur de monoacylglycérol lipase. Les compositions topiques peuvent être utilisées dans la gestion de la douleur neuropathique périphérique.
PCT/US2021/034845 2020-05-29 2021-05-28 Compositions topiques pour le traitement de la douleur neuropathique périphérique Ceased WO2021243201A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063031930P 2020-05-29 2020-05-29
US63/031,930 2020-05-29

Publications (1)

Publication Number Publication Date
WO2021243201A1 true WO2021243201A1 (fr) 2021-12-02

Family

ID=78722847

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2021/034845 Ceased WO2021243201A1 (fr) 2020-05-29 2021-05-28 Compositions topiques pour le traitement de la douleur neuropathique périphérique

Country Status (1)

Country Link
WO (1) WO2021243201A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008100977A2 (fr) * 2007-02-14 2008-08-21 N.V. Organon Agents de libération thérapeutiques
WO2019056123A1 (fr) * 2017-09-22 2019-03-28 Inmed Pharmaceuticals Inc. Formulations topiques de cannabinoïdes et leur utilisation dans le traitement de la douleur

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008100977A2 (fr) * 2007-02-14 2008-08-21 N.V. Organon Agents de libération thérapeutiques
WO2019056123A1 (fr) * 2017-09-22 2019-03-28 Inmed Pharmaceuticals Inc. Formulations topiques de cannabinoïdes et leur utilisation dans le traitement de la douleur

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ACHARYA ET AL.: "Solubility and Solubilization Approaches in Pharmaceutical Product Development", IN ADVANCES IN PHARMACEUTICAL PRODUCT DEVELOPMENT AND RESEARCH, DOSAGE FORM DESIGN CONSIDERATIONS, 2018, pages 513 - 547, DOI: https://doi.org/10.1016/B978-0-12-814423-7.00015-0 *
GIULIANO ET AL.: "Mucosal Applications of Poloxamer 407-Based Hydrogels: An Overview.", PHARMACEUTICS, vol. 10, no. 3, 12 September 2018 (2018-09-12), pages 1 - 26, XP055561701, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6161217> [retrieved on 20210921], DOI: 10.3390/pharmaceutics10030159 *
RUSSO S.: "WEED POWER : MILK THISTLE, LIVER DISEASE & THE ENDOCANNABINOID SYSTEM", .PROJECTCBD, 2 January 2017 (2017-01-02), pages 1 - 8, XP055877779, Retrieved from the Internet <URL:https://www.projectcbd.org/milk-thistle-liver-and-endocannabinoid-system> [retrieved on 20210802] *
SZAFRANIEC ET AL.: "The Self-Assembly Phenomenon of Poloxamers and Its Effect on the Dissolution of a Poorly Soluble Drug from Solid Dispersions Obtained by Solvent Methods", PHARMACEUTICS, vol. 11, no. 3, 19 March 2019 (2019-03-19), XP055877726, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6470807> [retrieved on 20210802], DOI: 10.3390/pharmaceutics11030130 *

Similar Documents

Publication Publication Date Title
Fiod Riccio et al. Characteristics, biological properties and analytical methods of trans-resveratrol: a review
Impellizzeri et al. Micronized/ultramicronized palmitoylethanolamide displays superior oral efficacy compared to nonmicronized palmitoylethanolamide in a rat model of inflammatory pain
JP7378402B2 (ja) カンナビノイドを含む放出調節組成物
Guida et al. Palmitoylethanolamide reduces pain-related behaviors and restores glutamatergic synapses homeostasis in the medial prefrontal cortex of neuropathic mice
Marchiori et al. Hydrogel containing silibinin-loaded pomegranate oil based nanocapsules exhibits anti-inflammatory effects on skin damage UVB radiation-induced in mice
Giordano et al. TRPV1-dependent and-independent alterations in the limbic cortex of neuropathic mice: impact on glial caspases and pain perception
Paleco et al. Enhancement of the in vitro penetration of quercetin through pig skin by combined microneedles and lipid microparticles
Esposito et al. A new co-micronized composite containing palmitoylethanolamide and polydatin shows superior oral efficacy compared to their association in a rat paw model of carrageenan-induced inflammation
Greene et al. Cannabidiol modulation of antinociceptive tolerance to Δ9-tetrahydrocannabinol
CN110545807B (zh) 用于治疗皮炎和炎性皮肤病的大麻素制剂
Permatasari et al. Quercetin prevent proteoglycan destruction by inhibits matrix metalloproteinase-9, matrix metalloproteinase-13, a disintegrin and metalloproteinase with thrombospondin motifs-5 expressions on osteoarthritis model rats
US20180235870A1 (en) Transdermal formulations for delivery of berberine compounds, and their use in the treatment of berberine-responsive diseases and conditions
AU2018350387A1 (en) Transdermal formulation for delivery of hydrophobic compounds and process for the preparation thereof
Bilge et al. Neuroprotective action of agmatine in rotenone-induced model of Parkinson’s disease: Role of BDNF/cREB and ERK pathway
De Filippis et al. Adelmidrol, a palmitoylethanolamide analogue, reduces chronic inflammation in a carrageenin‐granuloma model in rats
Lin et al. Topical delivery of four neuroprotective ingredients by ethosome-gel: synergistic combination for treatment of oxaliplatin-induced peripheral neuropathy
Li et al. Sanse Powder Essential Oil Nanoemulsion Negatively Regulates TRPA1 by AMPK/mTOR Signaling in Synovitis: Knee Osteoarthritis Rat Model and Fibroblast‐Like Synoviocyte Isolates
Police et al. Novel topical anandamide formulation for alleviating peripheral neuropathic pain
Wang et al. Preparing a novel baicalin-loaded microemulsion-based gel for transdermal delivery and testing its anti-gout effect
Biswasroy et al. Development of Betulin-loaded nanostructured lipid carriers for the management of Imiquimod-Induced Psoriasis
Ahmed et al. Premna odorata extract as a protective agent on neurotoxic effect of aluminum: neurochemical, molecular, and histopathological alterations
Attia et al. Topiramate affords neuroprotection in diabetic neuropathy model via downregulating spinal GFAP/inflammatory burden and improving neurofilament production
KR20240090226A (ko) 조합 산물을 사용한 신경계 장애를 치료하기 위한 조성물 및 방법
WO2021243201A1 (fr) Compositions topiques pour le traitement de la douleur neuropathique périphérique
Hu et al. Asiaticoside Attenuates Blood–Spinal Cord Barrier Disruption by Inhibiting Endoplasmic Reticulum Stress in Pericytes After Spinal Cord Injury

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21812200

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21812200

Country of ref document: EP

Kind code of ref document: A1